ANAB
AnaptysBio, Inc.
$48.73
+1.31%
2026-10-23
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Key Fundamentals
Forward P/E
9.21
EPS (TTM)
$-1.02
ROE
-114.6%
Revenue Growth (YoY)
23.5%
Profit Margin
247.0%
Debt/Equity
2546.89
Price/Book
116.17
Beta
0.41
Market Cap
$1.52B
Avg Volume (10D)
530K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$60.31
60D Low
$44.02
Avg Volume
497K
Latest Close
$48.73
Get breakout alerts for ANAB
Sign up for Breakout Scanner to receive daily notifications when ANAB triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
AnaptysBio, Inc. (ANAB) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ANAB daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ANAB operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.